Edition:
United Kingdom

Aldeyra Therapeutics Inc (ALDX.OQ)

ALDX.OQ on NASDAQ Stock Exchange Capital Market

6.50USD
14 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$6.50
Open
$6.50
Day's High
$6.65
Day's Low
$6.50
Volume
6,864
Avg. Vol
119,051
52-wk High
$11.90
52-wk Low
$3.80

Chart for

About

Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company... (more)

Overall

Beta: 0.64
Market Cap(Mil.): $136.71
Shares Outstanding(Mil.): 18.60
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Aldeyra Therapeutics Posts Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data

* ALDEYRA THERAPEUTICS PRESENTS NONINFECTIOUS ANTERIOR UVEITIS PHASE 2 CLINICAL TRIAL DATA TO THE AMERICAN UVEITIS SOCIETY HELD AT THE AMERICAN ACADEMY OF OPHTHALMOLOGY 2017 ANNUAL MEETING Source text for Eikon: Further company coverage:

29 Nov 2017

BRIEF-Aldeyra Therapeutics reports Q3 loss per share of $0.32

* Aldeyra Therapeutics announces third quarter 2017 financial results

09 Nov 2017

BRIEF-Aldeyra ‍announcesd new data for ADX-102 from Phase 2 clinical trials

* Aldeyra - ‍announced new clinical data for ADX-102 from recently completed Phase 2 clinical trials of dry eye disease and allergic conjunctivitis​

10 Oct 2017

BRIEF-Perceptive Advisors buys 200,000 shares of Aldeyra Therapeutics Inc's common stock on Sept 19

* Perceptive Advisors Llc reports purchase of 200,000 shares of Aldeyra Therapeutics Inc's common stock on Sept 19 at $7.25 per share - SEC filing

21 Sep 2017

BRIEF-Aldeyra Therapeutics posts pricing of public offering of common stock

* Aldeyra Therapeutics Inc announces pricing of public offering of common stock

19 Sep 2017

BRIEF-Aldeyra Therapeutics announces proposed public offering of common stock

* Aldeyra Therapeutics Inc announces proposed public offering of common stock

18 Sep 2017

BRIEF-Aldeyra Therapeutics announces positive results from dry eye disease phase 2A clinical trial

* Aldeyra Therapeutics announces positive results from dry eye disease phase 2A clinical trial Source text for Eikon: Further company coverage:

12 Sep 2017

BRIEF-Aldeyra Therapeutics Q2 loss per share $0.35

* Aldeyra therapeutics announces second quarter 2017 financial results

08 Aug 2017

BRIEF-Aldeyra Therapeutics expects to report results from phase 2A trial of topical ocular ADX-102 late in Q3

* Aldeyra Therapeutics-expects to report results from phase 2a trial of topical ocular ADX-102 late in Q3, 2017, not early in Q3 as stated in conf call Source text: (http://bit.ly/2rBbbkk) Further company coverage:

15 Jun 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $141.65 -1.24
Novartis AG (NOVN.S) CHF83.85 0.00
Pfizer Inc. (PFE.N) $36.46 -0.18
AbbVie Inc (ABBV.N) $96.30 -1.05
Amgen, Inc. (AMGN.OQ) $174.92 -2.46
Bristol-Myers Squibb Co (BMY.N) $62.13 -1.34
Bristol-Myers Squibb Co (BMYMP.PK) $1,060.00 --
UCB SA (UCB.BR) €64.06 -0.81

Earnings vs. Estimates